AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
2102
-
Likes:
7
-
Views:
2102
-
Likes:
7
-
Up Next -
10m 31s -
4m 41sPart 3 | Session 5 EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure -
6m 53s -
5m 6sPart 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy -
5m 7s -
4m 30sPart 3 | Session 9 ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF -
3m 49s -
5m 28sPart 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients -
3m 44sPart 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH -
3m 40sPart 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients -
Part 3 | Session 14 OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
-
29m 32sPart 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray
-
18m 41sPart 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen
-
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer
-
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle
-
22m 30sPart 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod
-
6m 17sPart 3 | Session 1 LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Dean J Kereiakes
-
3m 53sPart 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Frederick Raal
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
About the episode
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.
Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.
The REMS program investigated the safety and efficacy of mavacamten, a cardiac myosin inhibitor approved by the US FDA, which was monitored in over 5,500 symptomatic obstructive HCM patients. The primary outcome measure was the development of systolic heart failure and reduction of left ventricular ejection fraction.
Interview Questions:
1. What is the reasoning and data collection design behind the REMS program with mavacamten?
2. How do these results complement the REMS program?
Recorded on-site at AHA Conference in Chicago, 2024.
Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Milind Y Desai
Professor of Medicine
Dr Milind Desai works as the Director of the Hypertrophic Cardiomyopathy Center at the Heart, Vascular and Thoracic Institute at Cleveland Clinic. He also serves as a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
Alongside holding the Haslam Family Endowed Chair in Cardiovascular Medicine, Dr Desai has dual appointments in the Departments of Cardiovascular Medicine, within the Section of Cardiovascular Imaging, and Radiology. He is also a visiting professor at the University of Oxford, UK.
Dr Desai's clinical interests are heart valve disease, hypertrophic cardiomyopathy, aortic disorders, complex coronary artery disease, pericardial disease, and radiation heart disease. Dr Desai has a special interest in multimodality cardiovascular imaging, including echocardiogram, computed tomography (CT) scan and magnetic resonance imaging (MRI).
Comments